Recent events
Recent events tied to this brand in public sources.
Back to profile10 entries
2022
Johnson & Johnson and Remix Therapeutics form RNA research alliance
Johnson & Johnson and Remix Therapeutics announced a multi-drug research alliance. Johnson & Johnson is paying $45 million in upfront payment and research funding; its Janssen subsidiary receives exclusive rights to three targets with applications in immunology and oncology.
2022
Bayer and Janssen sue Micro Labs over Xarelto patents
Bayer Pharma AG, Bayer AG, and Janssen Pharmaceuticals Inc. filed a patent-infringement case against Micro Labs LTD and Micro Labs USA Inc. concerning Xarelto. The plaintiffs seek declaratory and injunctive relief and expenses.
2022
Midatech and Janssen extend Q-Sphera research collaboration
Midatech announced that it had extended its research and development collaboration with Janssen. The extended work will focus on maximizing drug loading and optimizing in vitro duration of release for an undisclosed Janssen experimental molecule using Q-Sphera technology.
2022
SRI International and Janssen announce collaboration
SRI International announced a collaboration agreement with Janssen to use SRI’s SynFini platform for small-molecule drug discovery and further platform development.
2021
Janssen agrees to supply COVID-19 vaccine doses to African Union members
Janssen Pharmaceutica N.V. signed an agreement with the African Vaccine Acquisition Trust to provide up to 220 million doses of its single-shot COVID-19 vaccine candidate to the African Union’s 55 member states starting in the third quarter of 2021. Supply depends on national regulatory approval or authorization.
2021
Morphic and Janssen expand research collaboration to a third integrin target
Morphic announced an expansion of its research and development collaboration with Janssen, initiating work on a third integrin target and including activating antibodies against that target.
2020
Janssen acquires rights to HMR59 gene therapy
Janssen Pharmaceuticals acquired from Hemera Biosciences the rights to HMR59, an investigational one-time intravitreal injection gene therapy being developed for geographic atrophy.
2020
Exonate and Janssen announce retinal disease treatment collaboration
Exonate announced a collaboration with Janssen Pharmaceuticals to develop eye drops for retinal vascular diseases, using mRNA-targeted therapies. The collaboration agreement was facilitated by Johnson & Johnson Innovation.
2020
Janssen completes acquisition of bermekimab rights
The Janssen Pharmaceutical Companies of Johnson & Johnson completed the acquisition from XBiotech of all rights to investigational bermekimab, along with certain employees, for $750 million.
2019
Encinitas sues opioid manufacturers and distributors
The city of Encinitas filed a lawsuit against multiple companies and parties in the opioid industry, alleging that manufacturers and distributors engaged in conduct that led doctors to prescribe opioids and neglected to warn consumers about their addictiveness. The suit named Teva Pharmaceutical Industries USA Inc., Janssen Pharmaceuticals Inc., AmerisourceBergen Corp. and Purdue Pharma's owners, the Sackler family.